Todays’ Rant
The Efficacy Rate of the coming Covid-19 Vaccines, should not even be an issue. It really doesn't matter whether they are 95%, 90%, 80%, or even 60%. The World has been using Influenza (flu) vaccine products, to assist in the protection of effects and death from the Flu illness, with much lesser Efficacy Rates. As with the Influenza (flu) Vaccines, few if anyone are expecting a Cure.
I would suggest that the main purposes of the Covid-19 Vaccine is to improve the body immune system strength, to fight off the effect of the Virus and at the same time, restrict the chance of the Virus passing from one individual to another. In this way the Covid-19 virus will find it more difficult to spread throughout the population. Much the same as what the Influenza (flu) Vaccine do.
Covid-19 Vaccine Side Effects: I find it ironic that some seem more worried about the possible side effects of potential Covid-19 Vaccines on individuals (on what is probably a select few), than they do about the actual impact of the Covid-19 virus on most people. To me, those who procrastinate over the Approval process of a vaccine and or its Release to the population, on argument that: it has a lower efficacy rate or because it may cause the death of a few individuals (whilst at the same tome saving many other) or that they simply need copious Data, simply have their head up their ar.se.
The longer they (Authorities) delay in decisions to release any of the potential vaccines, insisting on copious numbers of third stage human trial numbers and a plethora of data results, the more some people (those who could have been helped by a vaccine), will die.
For anyone to suggest that those highly experienced Virologist and reputable Research Laboratories are even undertaking research on a potential highly Toxic Vaccine, at this stage, one which is significantly dangerous to Humans, is just simply ludicrous. Not when the Companies have already taken the Vaccine through first and second stage trials. My understanding is that a Phase 2 human trail will test around 1000 people, I may be wrong.
I for one would certainly line up to take the vaccine after Phase 2 trails and for sure, more people would benefit from it, if it was to be released at the end of Phase 2 and not end of Phase 3
I am not sure of how long a Phase 3 Human Trail takes + then Collating the Data, + then Presenting & Obtaining CDC/FDA approval for release, of the Vaccine, but I dare say it is over 4 months and involves upward of 30,000 subjects and giving two Doses of the vaccine, from the Extract below.
How much Data do they really need to make a life-saving decision?
](./images/smilies/eusa_wall.gif "Brick wall")
Extract: The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina. The trial will continue to collect efficacy and safety data in participants for an additional two years.
PFZIER & Biontech Vaccine entered into their Phase 3 Trial on 27 July 2020, and at that time they obviously new that it was Safe for Humans, or they would not have moved forward to test it on 40,000 plus people. Four months later and how many died that potentially could have been saved in that 4 months?
I for one would ask, how many people would have benefited and even been spared death, had the PFZIER & Biontech Vaccine been released for personal choice use, particularly on the elderly (who could have said yes or no to it), much earlier. At worst straight after the Phase 3 Trial issue of the first Dose?
https://www.pfizer.com/news/press-relea ... 19-vaccine
EXTRACT:
CDC conducts studies each year to determine how well the influenza (flu) vaccine protects against flu illness. While vaccine effectiveness (VE) can vary, recent studies show that flu vaccination reduces the risk of flu illness by between 40% and 60% among the overall population during seasons when most circulating flu viruses are well-matched to the flu vaccine. In general, current flu vaccines tend to work better against influenza B and influenza A(H1N1) viruses and offer lower protection against influenza A(H3N2) viruses
How well the flu vaccine works (or its ability to prevent flu illness) can vary from season to season. The vaccine’s effectiveness also can vary depending on who is being vaccinated. At least two factors play an important role in determining the likelihood that flu vaccine will protect a person from flu illness: 1) characteristics of the person being vaccinated (such as their age and health), and 2) the similarity or “match” between the flu viruses the flu vaccine is designed to protect against and the flu viruses spreading in the community.
A 2018 study showed that from 2012 to 2015, flu vaccination among adults reduced the risk of being admitted to an intensive care unit (ICU) with flu by 82 percent.
The efficacy against the influenza A virus was 72 percent and for the inactivated was 29 percent with a relative efficacy of 60 percent. The influenza vaccine is not 100% efficacious in preventing disease, but it is as close to 100% safe, and much safer than the disease.
https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm
Had nothing better to do this morning, so thought that I would spend a few hours surfing the Net at work.
pipoz444
. housos rocks 
